Recent studies have shown that CBS promotes the growth of colon and ovarian cancer in preclinical models (Zhu et al., 2018), and CBS blockers have the potential as adjuvants in the treatment of breast cancer to reduce the ability of cancer cells to resist oxidative stress induced by many chemotherapeutic drugs (Sen et al., 2015). Here, CBS is linked to ovarian carcinoma.